Chronic obstructive pulmonary disease has recently been gaining more attention, as beyond impacting roughly 10% of the world's population, it also carries high morbidity and mortality. The mainstay of management is optimizing pharmacological therapy, but various nonpharmacological therapies have shown benefits in providing symptom improvement and relief, prevention and mitigation of exacerbations, quality of life, and even mortality rate. Such modalities include supplemental oxygen therapy, pulmonary rehabilitation, viral and bacterial vaccinations, and noninvasive positive pressure ventilation therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/CNQ.0000000000000337 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Soft tissue manipulation enhances recovery of muscle mass in a disuse model of sarcopenia.
J Osteopath Med
March 2025
Wood College of Osteopathic Medicine, Marian University, Indianapolis, IN, USA.
Context: Sarcopenia is a disease characterized by low muscle mass and function that places individuals at greater risk of disability, loss of independence, and death. Current therapies include addressing underlying performance issues, resistance training, and/or nutritional strategies. However, these approaches have significant limitations, and chronic inflammation associated with sarcopenia may blunt the anabolic response to exercise and nutrition.
View Article and Find Full Text PDFThe Effect of Electroencephalographic Biofeedback Therapy on Anxiety and Overall Well-being in Patients with Rectal Cancer.
Appl Psychophysiol Biofeedback
March 2025
Department of Pediatrics, Fourth Hospital of Hebei Medical University, NO. 12, JianKang Road, Hebei, Shijiazhuang, 050011, PR China.
This study aimed to investigate the effectiveness of electroencephalographic (EEG) biofeedback therapy in reducing anxiety levels and improving overall well-being among patients diagnosed with rectal cancer. A randomised controlled trial was conducted with 150 patients with rectal cancer who were randomly assigned to either the intervention group (n = 75) or the control group (n = 75). The intervention group received 16 sessions of EEG biofeedback therapy over 8 weeks, whereas the control group received standard care.
View Article and Find Full Text PDFIntegrating manual therapy into headache management: bridging the evidence gap.
Neurol Sci
March 2025
Department of Biomedical and Neuromotor Sciences (DIBINEM), Alma Mater Studiorum University of Bologna, Via Zamboni 33, Bologna, 40126, Italy.
Manual therapy remains an underutilized yet promising complementary intervention for headache management. Despite growing evidence supporting its efficacy, it is often overshadowed by pharmacological approaches and other non-pharmacological treatments such as acupuncture. This article highlights the potential role of manual therapy in reducing headache frequency and intensity, particularly in tension-type headaches and migraine.
View Article and Find Full Text PDFBeyond pills and prescriptions: Exploring aging-related diseases with non-pharmacological strategies and molecular innovations.
Aging Dis
February 2025
International Center for Neuroscience Research, Institute for Intelligent Research, Tbilisi, Georgia.
This paper provides a thorough examination of aging-related diseases, exploring into the intricate molecular mechanisms that underline their development and progression. It explores cutting-edge therapeutic interventions aimed at addressing these conditions, with a particular focus on non-pharmacological approaches such as personalized lifestyle modifications, cognitive enhancement strategies, and robust social engagement initiatives. Additionally, it highlights emerging modalities including gene therapy and precision medicine as promising avenues for mitigating the challenges associated with age-related ailments.
View Article and Find Full Text PDFTreatment options for depression in Parkinson's disease: a mini-review.
Int Clin Psychopharmacol
March 2025
Oasi Research Institute - IRCCS, Troina, Italy.
Depression is a common comorbidity in Parkinson's disease (PD), significantly reducing patients' quality of life. This mini-review examines pharmacological and nonpharmacological therapies for managing depression in PD, analyzing their benefits, and limitations. Pharmacological options include tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), levodopa, dopaminergic agonists, and monoamine oxidase B inhibitors.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!